每日两次放疗联合氟尿嘧啶/顺铂或每日一次放疗联合吉西他滨用于肌层浸润性膀胱癌的膀胱保留治疗:NRG/RTOG 0712-A 随机II期试验
该随机II期试验纳入cT2-4a肌层浸润性膀胱癌患者,比较氟尿嘧啶+顺铂联合每日两次放疗(FCT)与吉西他滨联合每日一次放疗(GD)的选择性膀胱保留治疗效果。共66例可分析,每组33例;3年无远处转移率FCT组78%、GD组84%,均超过75%的基准;GD组毒性更少。
要点
- FCT组与GD组3年无远处转移率分别为78%和84%,均超过75%的预设基准。
- 诱导化疗放疗后完全缓解率FCT组88%、GD组78%。
- FCT组21例(64%)发生治疗相关3-4级毒性,GD组18例(55%)。
核心结论
- 两种方案3年无远处转移率均大于75%,GD组观察到的毒性更少,吉西他滨联合每日一次放疗或顺铂为基础方案均可作为未来全身治疗试验的基础。
研究设计与样本
- 随机II期试验,2008年12月至2014年4月入组70例cT2-4a肌层浸润性膀胱癌患者,66例可分析,每组33例。
- 患者接受经尿道切除及诱导化疗放疗至40 Gy,完全缓解者接受巩固化疗放疗至64 Gy,其余行膀胱切除术,并给予辅助吉西他滨/顺铂化疗。
- 主要终点为3年无远处转移率(DMF3),试验未设定方案间统计学比较的效能,旨在评估任一方案是否超过75%的DMF3基准。
主要发现
- 可分析患者中位随访5.1年(范围0.4至7.8年)。
- DMF3在FCT组为78%,GD组为84%。
- 3年膀胱完整无远处转移生存率(BI-DMFS3)FCT组67%,GD组72%。
- 诱导后完全缓解率FCT组88%,GD组78%。
- FCT组33例中21例(64%)发生治疗相关3-4级毒性,其中3级和4级血液学毒性18例(55%)、胃肠道毒性2例(6%)、泌尿生殖毒性2例(6%);GD组33例中18例(55%)发生3-4级毒性,其中血液学14例(42%)、胃肠道3例(9%)、泌尿生殖2例(6%)。
关键数值与推荐
- 原文未报告推荐条款。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Fluorouracil plus cisplatin and radiation twice a day (FCT) is an established chemoradiation (CRT) regimen for selective bladder-sparing treatment of muscle-invasive bladder cancer. Gemcitabine and once daily radiation (GD) is a well-supported alternative. The current trial evaluates these regimens. METHODS: Patients with cT2-4a muscle-invasive bladder cancer were randomly assigned to FCT or GD. Patients underwent transurethral resection and induction CRT to 40 Gy. Patients who achieved a complete response (CR) received consolidation CRT to 64 Gy and others underwent cystectomy. We administered adjuvant gemcitabine/cisplatin chemotherapy. The primary end point was the rate of freedom from distant metastasis at 3 years (DMF3). The trial was not statistically powered to compare regimens, but to assess whether either regimen exceeded a DMF3 benchmark of 75%. Toxicity and efficacy end points, including CR and bladder-intact distant metastasis free survival at 3 years (BI-DMFS3), were assessed. RESULTS: From December 2008 to April 2014, 70 patients were enrolled, of which 66 were eligible for analysis, 33 per arm. Median follow-up was 5.1 years (range, 0.4 to 7.8 years) for eligible living patients. DMF3 was 78% and 84% for FCT and GD, respectively. BI-DMFS3 was 67% and 72%, respectively. Postinduction CR rates were 88% and 78%, respectively. Of 33 patients in the FCT arm, 21 (64%) experienced treatment-related grade 3 and 4 toxicities during protocol treatment, with 18 (55%), two (6%), and two patients (6%) experiencing grade 3 and 4 hematologic, GI, and genitourinary toxicity, respectively. For the 33 patients in the GD arm, these figures were 18 (55%) overall and 14 (42%), three (9%) and two patients (6%), respectively. CONCLUSION: Both regimens demonstrated DMF3 greater than 75%. There were fewer toxicities observed in the GD arm. Either gemcitabine and once daily radiation or a cisplatin-based regimen could serve as a base for future trials of systemic therapy.
引用
- Coen JJ, Zhang P, Saylor PJ, et al. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2018. PMID: 30433852. doi:10.1200/JCO.18.00537
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。